Renovaro /
Predictive Oncology
Renovaro pursues acquisition of Predictive Oncology




What happened
Renovaro and Predictive Oncology extended their letter of intent for the proposed acquisition of Predictive Oncology’s capital stock. The extension moves the letter’s outside termination date to March 31, 2025.
The transaction remains subject to a definitive agreement and approval by Predictive Oncology stockholders.
The source
Everything on this page comes from the source below.
Renovaro pursues acquisition of Predictive Oncology
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verifiedAlso stated
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly